Infigratinib (BGJ-398; NVP-BGJ398) is a potent, orally available FGFR inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. It also inhibits VEGFR2 (IC50 = 180 nM) while showing minimal activity against other kinases. Infigratinib suppresses proliferation in cancer cells overexpressing wild-type FGFR3 and inhibits tumor growth in an RT112 bladder cancer xenograft mouse model at doses of 10-30 mg/kg. Reagent grade, for research purpose.
Usually ships within 24 hours.